XTX Topco Ltd Increases Stock Position in Xencor, Inc. (NASDAQ:XNCR)

XTX Topco Ltd increased its position in Xencor, Inc. (NASDAQ:XNCR - Free Report) by 191.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 54,209 shares of the biopharmaceutical company's stock after buying an additional 35,627 shares during the period. XTX Topco Ltd owned 0.08% of Xencor worth $577,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in XNCR. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Xencor during the 1st quarter valued at about $135,000. Y Intercept Hong Kong Ltd acquired a new position in Xencor during the 1st quarter valued at about $528,000. CWM LLC boosted its stake in Xencor by 195.5% during the 1st quarter. CWM LLC now owns 3,372 shares of the biopharmaceutical company's stock valued at $36,000 after purchasing an additional 2,231 shares during the last quarter. Principal Financial Group Inc. boosted its stake in Xencor by 2.5% during the 1st quarter. Principal Financial Group Inc. now owns 348,726 shares of the biopharmaceutical company's stock valued at $3,710,000 after purchasing an additional 8,581 shares during the last quarter. Finally, New York State Teachers Retirement System boosted its stake in Xencor by 2.1% during the 1st quarter. New York State Teachers Retirement System now owns 59,326 shares of the biopharmaceutical company's stock valued at $631,000 after purchasing an additional 1,200 shares during the last quarter.

Xencor Trading Down 1.2%

Shares of NASDAQ:XNCR traded down $0.09 during mid-day trading on Friday, reaching $7.23. The company had a trading volume of 872,504 shares, compared to its average volume of 608,290. The firm has a market cap of $515.67 million, a price-to-earnings ratio of -3.01 and a beta of 0.89. The company's 50-day moving average price is $8.67 and its 200-day moving average price is $10.94. Xencor, Inc. has a one year low of $7.07 and a one year high of $27.24.

Xencor (NASDAQ:XNCR - Get Free Report) last issued its earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.78) by $0.37. Xencor had a negative net margin of 121.52% and a negative return on equity of 25.75%. The business had revenue of $43.61 million for the quarter, compared to analysts' expectations of $22.59 million. During the same quarter in the previous year, the firm posted ($1.07) EPS. The business's revenue for the quarter was up 82.4% compared to the same quarter last year. On average, research analysts anticipate that Xencor, Inc. will post -3.68 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on XNCR. Barclays cut their price target on Xencor from $22.00 to $6.00 and set an "underweight" rating for the company in a research note on Thursday, May 8th. William Blair began coverage on Xencor in a research note on Monday, April 21st. They set an "outperform" rating for the company. Wedbush cut their target price on Xencor from $31.00 to $26.00 and set an "outperform" rating on the stock in a research note on Thursday. Finally, Wells Fargo & Company cut their target price on Xencor from $33.00 to $27.00 and set an "overweight" rating on the stock in a research note on Thursday. Two equities research analysts have rated the stock with a sell rating and seven have issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $26.43.

Insider Buying and Selling

In related news, Director Richard J. Ranieri sold 2,993 shares of the company's stock in a transaction on Monday, June 16th. The shares were sold at an average price of $9.22, for a total value of $27,595.46. Following the completion of the transaction, the director directly owned 19,183 shares in the company, valued at approximately $176,867.26. The trade was a 13.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Kurt A. Gustafson sold 2,993 shares of the company's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $9.22, for a total transaction of $27,595.46. Following the sale, the director owned 20,183 shares of the company's stock, valued at approximately $186,087.26. The trade was a 12.91% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 11,194 shares of company stock worth $103,209. Corporate insiders own 4.76% of the company's stock.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.